Case Report Describes Possible Betahistine–Suicidality Link - Report - MDSpire
Advertisement
Case Report Describes Possible Betahistine–Suicidality Link
A single case report described suicidal ideation that resolved after betahistine discontinuation and recurred after rechallenge, but the findings cannot establish causality or quantify risk.
Clinical Report: Case Report Describes Possible Betahistine–Suicidality Link
Overview
This case report describes a potential association between betahistine use and the emergence of depressive symptoms with suicidal ideation in a 33-year-old male patient.
Background
Betahistine is commonly used for treating vertigo and Ménière disease, despite not being FDA-approved. With over 100 million estimated patient exposures globally, understanding its safety profile, particularly concerning suicidality, is critical for clinicians. This case report highlights a previously unreported potential link between betahistine and suicidality.
Data Highlights
No numerical or trial data presented in the article.
Key Findings
A 33-year-old male developed low mood and suicidal ideation after starting betahistine.
Symptoms resolved within 2 days after discontinuation of betahistine.
The case was classified as a probable adverse drug reaction based on established assessment scales.
Prior safety signals indicated betahistine as a risk factor for suicide attempts.
Clinical Implications
Clinicians should be aware of the potential for neuropsychiatric adverse reactions in patients treated with betahistine.
Conclusion
This case report presents a potential psychiatric side effect associated with betahistine.
